Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review
- PMID: 20719825
- PMCID: PMC2923692
- DOI: 10.1136/bmj.c3920
Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review
Abstract
Objective: To study how composite outcomes, which have combined several components into a single measure, are defined, reported, and interpreted.
Design: Systematic review of parallel group randomised clinical trials published in 2008 reporting a binary composite outcome. Two independent observers extracted the data using a standardised data sheet, and two other observers, blinded to the results, selected the most important component.
Results: Of 40 included trials, 29 (73%) were about cardiovascular topics and 24 (60%) were entirely or partly industry funded. Composite outcomes had a median of three components (range 2-9). Death or cardiovascular death was the most important component in 33 trials (83%). Only one trial provided a good rationale for the choice of components. We judged that the components were not of similar importance in 28 trials (70%); in 20 of these, death was combined with hospital admission. Other major problems were change in the definition of the composite outcome between the abstract, methods, and results sections (13 trials); missing, ambiguous, or uninterpretable data (9 trials); and post hoc construction of composite outcomes (4 trials). Only 24 trials (60%) provided reliable estimates for both the composite and its components, and only six trials (15%) had components of similar, or possibly similar, clinical importance and provided reliable estimates. In 11 of 16 trials with a statistically significant composite, the abstract conclusion falsely implied that the effect applied also to the most important component.
Conclusions: The use of composite outcomes in trials is problematic. Components are often unreasonably combined, inconsistently defined, and inadequately reported. These problems will leave many readers confused, often with an exaggerated perception of how well interventions work.
Conflict of interest statement
Competing interests: None declared.
Figures
Comment in
-
Interpreting composite outcomes in trials.BMJ. 2010 Aug 18;341:c3529. doi: 10.1136/bmj.c3529. BMJ. 2010. PMID: 20719822 No abstract available.
-
"Cherry picking" did not occur in studied example.BMJ. 2010 Sep 15;341:c5009. doi: 10.1136/bmj.c5009. BMJ. 2010. PMID: 20843921 No abstract available.
References
-
- Ferreira-Gonzalez I, Permanyer-Miralda G, Busse JW, Bryant DM, Montori VM, Alonso-Coello P, et al. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J Clin Epidemiol 2007;60:651-7. - PubMed
-
- Ross S. Composite outcomes in randomized clinical trials: arguments for and against. Am J Obstet gynecol 2007;196:119e1-6. - PubMed
-
- Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289:2554-9. - PubMed
-
- Tomlinson G, Detsky AS. Composite end points in randomized trials: there is no free lunch. JAMA 2010;303:267-8. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources